eXmoor Pharma MD named as a leading woman in UK healthcare businesses

Healthcare | South East

eXmoor Pharma managing director Angela Osborne has been named in BioBeat’s ‘50 Movers and Shakers’ which lists the most influential women in UK healthcare businesses.

Angela founded the biopharmaceutical and cell therapy manufacturing consultancy eXmoor Pharma in 2004 and has since grown it into a globally recognised leader in its field that has completed more than 300 projects across 12 countries.

In September 2010 she co-founded the Advanced Therapy Medicinal Products (ATMP) Manufacturing Community, or amc, to build critical mass and facilitate the sharing of expertise in ATMP manufacturing. The amc now boasts 170 fee paying members.

Angela is a member of the BioIndustry Association (BIA)’s Cell Therapy Industry Group and Manufacturing Groups’ advisory committees. She has now been named alongside 49 other ‘outstanding’ female healthcare business leaders in the 2018 BioBeat list which aims to emphasise the role of women leading and innovating to ensure new technologies and treatments continue to improve UK research, health and society.

Angela said: “It is a real honour to be included on this BioBeat list alongside so many other inspiring women working in UK healthcare businesses. There is amazing work being done by women across the board developing new products and processes and pushing the boundaries of bioscience in ways that will hopefully benefit everyone in years to come.

“My inclusion on this list is really thanks to the hard work and dedication of all our talented team at eXmoor who between them have more than 300 years’ combined experience in gene and cell therapy and biopharmaceuticals.”

eXmoor Pharma works closely with clients to help them with commercialising a research process, developing fully licensed facilities and providing QP services. The company has won repeat business from nearly two thirds of all its clients since its launch.

Did you enjoy reading this content?  To get more great content like this subscribe to our magazine

Reader's Comments

Comments related to the current article

Leave a comment